Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Quick Stats
Jan 30, 202654.6
AI Score
HOLD0.38
Volume Ratio
Feb 13, 2026
Next Earnings
11
+ve Days (30d)
17
-ve Days (30d)
CTOR Stock Summary
Last updated Jan 30, 2026
CTOR is currently trading at $1.06, positioned below its 200-day moving average of $1.59, suggesting bearish momentum. The stock has a 52-week range of $0.5506 to $6.19.
Technical Analysis: The 50-day moving average stands at $1.15, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 43.556, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.049, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates CTOR at 54.6/100 with a HOLD recommendation.
CTOR (Citius Oncology, Inc. Common Stock) Indicators
Last updated Jan 30, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 43.556 |
| CMF (20) | 0.049 |
| ROC (10) | -1.852 |
| ADX (14) | 9.005 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.024 |
| AROONOSC (14) | 50.0 |
| WILLAMS %R (14) | -75.0 |
| MFI (14) | 53.741 |
CTOR Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
CTOR Price vs Max Options Open Interest
CTOR Max Change In Options Open Interest
CTOR Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
CTOR Daily Out of Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
CTOR Daily In the Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
CTOR Most Active Options by Volume(near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Citius Oncology, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
CTOR Moving Averages Analysis
CTOR (Citius Oncology, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Jan 30, 2026
| Days | MA |
|---|---|
| 10 | 1.1 |
| 20 | 1.1 |
| 30 | 1.12 |
| 50 | 1.15 |
| 100 | 1.44 |
| 200 | 1.59 |
CTOR Fundamental Analysis
| P/E (Forward) | 35.5872 |
| P/E (Trailing) | -- |
| Market Cap ($) | 93.6 million |
| Earnings/Share ($) | -0.34 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.14 |
| EPS Estimate Next Year ($) | 0.67 |
| WallStreet Target Price ($) | 6 |
| Most Recent Quarter |